PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
While Cogent joins the FGFR party.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Just when investors thought things couldn't get any worse, they do.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
